Digest Network Come funziona
Network
/
Società
Ve
Non verificato

Vedanta Biosciences

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati
09/04/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Vedanta Biosciences Showcases Innovative Work on its Microbiome-based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 Global Congress
Fonte
Vedanta Biosciences
Emittente
Business Wire
1.00
0
02/04/2026
Industria
Igiene alimentare
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
Fonte
Vedanta Biosciences
Emittente
Business Wire
1.00
0
13/08/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
Fonte
Vedanta Biosciences
Emittente
Business Wire
1.00
0
23/01/2025
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Fonte
Vedanta Biosciences
Emittente
Business Wire
1.00
0
16/10/2024
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
Fonte
Vedanta Biosciences
Emittente
Business Wire
1.00
0
23/07/2024
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
Fonte
Vedanta Biosciences
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0